Literature DB >> 32524658

Evaluating the Relationship Between Dynamic Contrast-Enhanced MRI (DCE-MRI) Parameters and Pathological Characteristics in Breast Cancer.

Se Ri Kang1, Hye Won Kim2, Hun Soo Kim3.   

Abstract

BACKGROUND: Dynamic contrast-enhanced MRI (DCE-MRI) is used to evaluate tumor microvasculature. However, studies demonstrating an association between perfusion parameters derived from DCE-MRI and histopathologic characteristics are limited to a small set of histopathologic factors, and the results are inconsistent.
PURPOSE: To evaluate the relationship between DCE-MRI perfusion parameters and common histopathologic tumor characteristics used to predict angiogenesis and determine prognosis in breast cancer. STUDY TYPE: Retrospective. POPULATION: In all, 105 breast cancer patients with invasive ductal carcinoma (122 lesions). FIELD STRENGTH/SEQUENCE: 3.0T, turbo spin-echo (TSE) T1 -weighted, fat-suppressed T2 -weighted, TSE T2 -weighted, and dynamic unenhanced and contrast-enhanced 3D T1 high-resolution isotropic volume examination. ASSESSMENT: One reviewer obtained perfusion parameters (Ktrans , kep , ve , and vp ) of each breast cancer from DCE MRI using the extended Tofts model with a fixed baseline T1 value and a population-based arterial input function. The relationship between DCE-MRI perfusion parameters and histopathologic tumor characteristics used to predict angiogenesis and determine prognosis was evaluated. STATISTICAL TESTS: Student's t-test, Mann-Whitney U-test, analysis of variance (ANOVA), and Kruskal-Wallis test were used.
RESULTS: Triple-negative breast cancers exhibited higher Ktrans and kep than luminal cancers (P < 0.05). Estrogen receptor (ER)-negative tumors showed higher Ktrans than ER-positive tumors (P < 0.05). Progesterone receptor (PR)-negative tumors presented higher ve than PR-positive tumors (P < 0.05). Tumors with higher Ki-67 showed higher kep than tumors with lower Ki-67 (P < 0.05). P53-positive tumors exhibited higher Ktrans and kep than p53-negative tumors (P < 0.05). Higher histologic grade tumors (grade II/III) presented higher Ktrans , kep , vp (P < 0.05) than grade I tumors. Tumors with LVSI presented higher Ktrans and kep than tumors without LVSI (P < 0.05). DATA
CONCLUSION: Breast cancer presenting higher Ktrans and kep on DCE-MRI was associated with poor prognostic histopathologic factors. Therefore, pretreatment DCE-MRI perfusion parameters may be useful imaging biomarkers for the evaluation of tumor prognosis and angiogenesis. LEVEL OF EVIDENCE: 3 TECHNICAL EFFICACY STAGE: 2.
© 2020 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  angiogenesis; breast neoplasm; magnetic resonance imaging; perfusion; prognosis

Mesh:

Substances:

Year:  2020        PMID: 32524658     DOI: 10.1002/jmri.27241

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  9 in total

1.  Associations Between Dynamic Contrast Enhanced Magnetic Resonance Imaging and Clinically Relevant Histopathological Features in Breast Cancer: A Multicenter Analysis.

Authors:  Alexey Surov; Jin You Kim; Marco Aiello; Wei Huang; Thomas E Yankeelov; Andreas Wienke; Maciej Pech
Journal:  In Vivo       Date:  2022 Jan-Feb       Impact factor: 2.155

Review 2.  Dynamic contrast-enhanced (DCE) imaging: state of the art and applications in whole-body imaging.

Authors:  Domenico Albano; Federico Bruno; Andrea Agostini; Salvatore Alessio Angileri; Massimo Benenati; Giulia Bicchierai; Michaela Cellina; Vito Chianca; Diletta Cozzi; Ginevra Danti; Federica De Muzio; Letizia Di Meglio; Francesco Gentili; Giuliana Giacobbe; Giulia Grazzini; Irene Grazzini; Pasquale Guerriero; Carmelo Messina; Giuseppe Micci; Pierpaolo Palumbo; Maria Paola Rocco; Roberto Grassi; Vittorio Miele; Antonio Barile
Journal:  Jpn J Radiol       Date:  2021-12-24       Impact factor: 2.374

3.  Pharmacokinetic Analysis of Dynamic Contrast-Enhanced Magnetic Resonance Imaging at 7T for Breast Cancer Diagnosis and Characterization.

Authors:  R Elena Ochoa-Albiztegui; Varadan Sevilimedu; Joao V Horvat; Sunitha B Thakur; Thomas H Helbich; Siegfried Trattnig; Elizabeth A Morris; Jeffrey S Reiner; Katja Pinker
Journal:  Cancers (Basel)       Date:  2020-12-14       Impact factor: 6.639

4.  Correlation of DCE-MRI Perfusion Parameters and Molecular Biology of Breast Infiltrating Ductal Carcinoma.

Authors:  Li Liu; Nan Mei; Bo Yin; Weijun Peng
Journal:  Front Oncol       Date:  2021-10-13       Impact factor: 6.244

5.  Value of breast MRI omics features and clinical characteristics in Breast Imaging Reporting and Data System (BI-RADS) category 4 breast lesions: an analysis of radiomics-based diagnosis.

Authors:  Dongxue Qin; Yiping Zhao; Qian Cui; Liang Sun; Yu Zhang; Zimu Zhao; Shuo Li; Yajie Liu; Hongwei Ge
Journal:  Ann Transl Med       Date:  2021-11

6.  PET/MR Imaging of Somatostatin Receptor Expression and Tumor Vascularity in Meningioma: Implications for Pathophysiology and Tumor Outcomes.

Authors:  Michelle Roytman; Sean Kim; Shannon Glynn; Charlene Thomas; Eaton Lin; Whitney Feltus; Rajiv S Magge; Benjamin Liechty; Theodore H Schwartz; Rohan Ramakrishna; Nicolas A Karakatsanis; Susan C Pannullo; Joseph R Osborne; Jonathan P S Knisely; Jana Ivanidze
Journal:  Front Oncol       Date:  2022-01-28       Impact factor: 6.244

7.  An MRI-Based Clinical-Perfusion Model Predicts Pathological Subtypes of Prevascular Mediastinal Tumors.

Authors:  Chia-Ying Lin; Yi-Ting Yen; Li-Ting Huang; Tsai-Yun Chen; Yi-Sheng Liu; Shih-Yao Tang; Wei-Li Huang; Ying-Yuan Chen; Chao-Han Lai; Yu-Hua Dean Fang; Chao-Chun Chang; Yau-Lin Tseng
Journal:  Diagnostics (Basel)       Date:  2022-04-02

8.  Effect of Neoadjuvant Chemotherapy on Angiogenesis and Cell Proliferation of Breast Cancer Evaluated by Dynamic Enhanced Magnetic Resonance Imaging.

Authors:  Lifang Chang; Honglin Lan
Journal:  Biomed Res Int       Date:  2022-07-23       Impact factor: 3.246

Review 9.  Applying artificial intelligence technology to assist with breast cancer diagnosis and prognosis prediction.

Authors:  Meredith A Jones; Warid Islam; Rozwat Faiz; Xuxin Chen; Bin Zheng
Journal:  Front Oncol       Date:  2022-08-31       Impact factor: 5.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.